Reflecting on a decade subsequent to the consequential Supreme Court decision in Federal Trade Commission v. Actavis, it’s clear that this ruling fundamentally reshaped pharmaceutical antitrust law, by simultaneously defining “reverse payment settlements” and affirming that antitrust liability can apply to these settlements. Initially aiming to steer clear of instant condemnation of such settlements, the Actavis verdict has since mutated each Hatch-Waxman patent litigation agreement into an antitrust affair.
Indeed, courtesy of its broad-ranging, fact-heavy nature, the Actavis ruling continues to be a point of discussion amongst legal professionals and corporations worldwide, continually forcing a reevaluation of Hatch-Waxman litigation. In essence, it served as a catalyst to reform several aspects of patent law, steering it towards a more monopolistic scrutiny.
In retrospect, we can now see how Actavis furnished significant input to the discourse on how antitrust laws can be applied to reverse payment settlements. Therefore, its principles have extended well beyond the niche sector of Hatch-Waxman patent litigation, infiltrating wider pharmaceutical industry operations. Firms now acquiesce to the oversight of their settlement agreements, their strategies for reaching such, and, inevitably, their stance on patent and brand strategy.
More than just a mere ruling, Actavis has been a major legal influence that has dictated the trajectory of patent agreements, lawsuits, and antitrust lawsuits over the past 10 years. It has not only fine-tuned the manner in which Hatch-Waxman settlements are scrutinized but also served as a touchstone for corporations and their legal representatives to regularly calibrate their actions against. This tale of continued influence is the true story of the Actavis decision, one which lawyers, corporations, and industry leaders have spent the last decade writing.